An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

Recruiting

Phase 1

Phase 2

PovetaciceptAn Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

Sponsor:

Alpine Immune Sciences, Inc.

Code:

NCT05732402

Conditions

Lupus Nephritis

Immunoglobulin A Nephropathy

Membranous Nephropathy

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Povetacicept

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by Alpine Immune Sciences, Inc. on 2025-03-06.